More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud ...

| Adopting an RTU vial setup for aseptic filling process can help optimize operational efficiency, reduce TCO, and comply ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...

This fall, Fierce Pharma Marketing launched a running series of Q&A features celebrating up-and-comers in our corner of the ...

When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

A recent survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of ...

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...

Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...

The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...

The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.